U.S. Colcrys Promotional Audit Report 2017-2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 12, 2018--The “Colcrys 2017 U.S. Promotional Audit Report” report has been added to ResearchAndMarkets.com’s offering.
The 5 Key Questions Addressed by this Report:How many physicians were reached by Colcrys through reportable promotional activity in 2017 and how does this compare to its peer set in the Familial Mediterranean Fever and Gout markets? What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend for each type of activity? How does Takeda’s depth of coverage vary within key specialties (e.g., Family Medicine and Internal Medicine) and how does this compare to its peers and the overall set of rep-accessible physicians? How often are physicians receiving paid meals for Colcrys throughout the year (e.g., monthly, quarterly, annually)? Who were the most frequent meal recipients and top paid speakers for Colcrys in 2017?
Data Sources and Methodology:The author leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. More than four years of longitudinal data is available - covering payments to more than 975,000 U.S. healthcare professionals. Over 1,800 paid interactions across 1,300 physicians made on behalf of Colcrys were carefully examined to support our analysis. For more information about this report visit https://www.researchandmarkets.com/research/k7t4cx/u_s_colcrys?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180912005966/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Immune Disorders Drugs
KEYWORD: UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/12/2018 02:46 PM/DISC: 09/12/2018 02:46 PM